Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

NCT02279732 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

342

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer (NSCLC)

Interventions

BIOLOGICAL: Paclitaxel
BIOLOGICAL: Carboplatin
BIOLOGICAL: Ipilimumab
OTHER: Placebo

Sponsor

Bristol-Myers Squibb